TABLE 4.

Demographic, clinical manifestations and antimicrobial resistance among iNTS and non-iNTS infections in 2012 and 2019.

	iNTS infections (n = 62)	Non-iNTS infections (n = 555)	P value
Male, n (%)	53.2% (33)	56.5% (314)	0.582
Age, y/o, mean ± SD	1.7 ± 2.8	2.3 ± 2.3	0.099
Symptoms at admission
Fever, n (%)	58(93.5%)	512(92.8%)	0.930
Diarrhea, n (%)	45(72.6%)	376(68.1%)	0.444
Bloody stools, n (%)	19(43.2%)	242(58%)	0.059
Abdominal pain, n (%)	9(14.5%)	186(33.7%)	0.001
Vomiting, n (%)	18(29%)	208(37.3%)	0.087
Fever duration, days, mean ± SD	3.8 ± 2.4	2.7 ± 2.1	< 0.001
Hospital stay, days, mean ± SD	9.8 ± 9.5	5.8 ± 12.1	0.016
Hb, g/dL, mean ± SD	11.6 ± 1.4	12.1 ± 1.2	0.027
CRP, mg/L, mean ± SD	39.1 ± 58.3	58.6 ± 54.8	0.009
Band form, %, mean ± SD	4.7 ± 6.9	6.9 ± 6.9	0.112
WBC, /μl, mean ± SD	10,803 ± 4,420	10,051 ± 4,168	0.192
Antimicrobial resistance
2019
Ampicillin	29.7%	41.6%	0.165
Ceftriaxone	5.4%	14.8%	0.119
Ertapenem	2.7%	0.3%	0.209
Imipenem	2.8%	1.0%	0.353
Ciprofloxacin	30.6%	28.5%	0.790
TMP-SMX	20.6%	30.2%	0.240
Chloramphenicol	66.7%	29.9%	0.073
Flomoxef	40%	5.5%	0.030
2012
Ampicillin	42.1%	49.7%	0.519
Ceftriaxone	10.5%	3.8%	0.182
Ertapenem	0%	0%	NA
Imipenem	0%	0%	NA
Ciprofloxacin	5.3%	1.7%	0.316
TMP-SMX	15.8%	27.9%	0.248
Chloramphenicol	21.1%	21.8%	1.000
Flomoxef	5.3%	3.2%	0.624

iNTS, invasive non-typhoidal Salmonella; SD, standard deviation; TMP-SMX, trimethoprim-sulfamethoxazole.